Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

Xenobiotica

Volumn 40, Issue 3, 2010, Pages 163-176

  Annaert, P ^a   Ye, Z W ^a   Stieger, B ^b   Augustijns, P ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Drug interaction; Hepatic drug transport; Human immunodeficiency virus (HIV) protease inhibitor; Organic anion transporting polypeptide (OATP)

Indexed keywords

AMPRENAVIR; ATAZANAVIR; BILE SALT; BROMSULFOPHTHALEIN; CHOLYLGLYCYLAMIDO FLUORESCEIN; DARUNAVIR; DIGOXIN; ESTRONE SULFATE; INDINAVIR; LOPINAVIR; NELFINAVIR; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2B1; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BIOACCUMULATION; CELL CULTURE; CELL STRAIN CACO 2; CHO CELL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER; MONOLAYER CULTURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANIMALS; CACO-2 CELLS; CHO CELLS; CRICETINAE; CRICETULUS; ESTRONE; FLUORESCEINS; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; TRANSFECTION;

CRICETULUS GRISEUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77149153424     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903509375     Document Type: Article

References (52)

1. Annaert PP, Brouwer KL. (2005). Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33:388-394
2. Annaert PP, Swift B, Lee JK, Brouer KLR. (2007). Drug transporters: molecular characterization and role in drug disposition. In: You G, Morris M, eds. Drug transport in the liver, New York, NY: Wiley, p 359-410.
3. Ayrton A, Morgan P. (2008). Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676-708.
4. Bravo P, Bender V, Cassio D. (1998). Efficient in vitro vectorial transport of a fluorescent conjugated bile acid analogue by polarized hepatic hybrid WIF-B and WIF-B9 cells. Hepatology 27:576-583
5. Chandwani A, Shuter J. (2008). Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023-1033
6. Cheng Y, Prusoff WH. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
7. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. (2003). Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55:94-99
8. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter, MXR. Cancer Lett 146:117-126
9. DuBuske LM. (2005). The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 28:789-801.
10. Endres CJ, Hsiao P, Chung FS, Unadkat JD. (2006). The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517
11. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. (1995). The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208:345-352
12. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, Hagenbuch B. (2008). Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57-65.
13. Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
14. Hagenbuch B, Meier PJ. (2003). The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
15. Hagenbuch B, Scharschmidt BF, Meier PJ. (1996). Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem J 316:901-904
16. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Mullertz A, Monkkonen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. (2008). Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-396
17. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340
18. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236
19. Hoetelmans R VdSI, Pauw MD, Struble K, Peeters M, Van der Geest R. (2003). TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA.
20. Holzinger F, Schteingart CD, Ton-Nu HT, Cerre C, Steinbach JH, Yeh HZ, Hofmann AF. (1998). Transport of fluorescent bile acids by the isolated perfused rat liver: kinetics, sequestration, and mobilization. Hepatology 28:510-520
21. Huang L, Wang Y, Grimm S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742
22. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. (2008). Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47:570-578
23. Konig J, Seithel A, Gradhand U, Fromm MF. (2006). Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432-443
24. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. (2001). Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533
25. Letschert K, Faulstich H, Keller D, Keppler D. (2006). Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91:140-149
26. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. (2008). SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799
27. Maglova LM, Jackson AM, Meng XJ, Carruth MW, Schteingart CD, Ton-Nu HT, Hofmann AF, Weinman SA. (1995). Transport characteristics of three fluorescent conjugated bile acid analogs in isolated rat hepatocytes and couplets. Hepatology 22:637-647
28. Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. (2007). Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 51:2035-2042
29. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD. (2006). Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318:1068-1075
30. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. (2006). Inhibition of bile acid transport across Na+/ taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581
31. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602-604 (Pubitemid 40632253)
32. Noe J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308-1314
33. Perry CM, Frampton JE, McCormack PL, Siddiqui MA, Cvetkovic RS. (2005). Nelfinavir: a review of its use in the management of HIV infection. Drugs 65:2209-2244
34. Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA. (2007). Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 51:560-565
35. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. (2006). Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone 3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423-1431
36. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481
37. Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharmaceut Sci 27:425-446
38. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177
39. Soars MG, McGinnity DF, Grime K, Riley RJ. (2007). The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15.
40. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Sugiyama Y. (2002). Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. Drug Metab Dispos 30:220-223
41. Swainston Harrison T, Scott LJ. (2005). Atazanavir: a review of its use in the management of HIV infection. Drugs 65:2309-2336
42. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. (2001). Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269
43. Treiber A, Schneiter R, Hausler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400-1407
44. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW. (2006). Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46:758-767
45. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172
46. Wallstab A, Koester M, Bohme M, Keppler D. (1999). Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer 79:1053-1060
47. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, Hidalgo IJ. (2008). Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharmaceut 356:12-18.
48. Williams GC, Sinko PJ. (1999). Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211-238
49. Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. (2009). Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet Genomics 19:447-457
50. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. (2005). Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35:737-753
51. Ye ZW, Augustijns P, Annaert P. (2008). Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1315-1321
52. Ye ZW, van Pelt J, Camus S, Snoeys J, Augustijns P, Annaert P. (Forthcoming 2010). Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes. J Pharm Sci (In Press).